These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15040941)

  • 1. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.
    Fattom AI; Horwith G; Fuller S; Propst M; Naso R
    Vaccine; 2004 Feb; 22(7):880-7. PubMed ID: 15040941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A; Fuller S; Propst M; Winston S; Muenz L; He D; Naso R; Horwith G
    Vaccine; 2004 Dec; 23(5):656-63. PubMed ID: 15542186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcus aureus vaccine conjugate--Nabi: Nabi-StaphVAX, StaphVAX.
    Drugs R D; 2003; 4(6):383-5. PubMed ID: 14584973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. StaphVAX (Nabi).
    Jones T
    Curr Opin Investig Drugs; 2002 Jan; 3(1):48-50. PubMed ID: 12054071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
    Shinefield H; Black S; Fattom A; Horwith G; Rasgon S; Ordonez J; Yeoh H; Law D; Robbins JB; Schneerson R; Muenz L; Fuller S; Johnson J; Fireman B; Alcorn H; Naso R
    N Engl J Med; 2002 Feb; 346(7):491-6. PubMed ID: 11844850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination and passive immunisation against Staphylococcus aureus.
    Schaffer AC; Lee JC
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S71-8. PubMed ID: 18757184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.
    Robbins JB; Schneerson R; Horwith G; Naso R; Fattom A
    Am Heart J; 2004 Apr; 147(4):593-8. PubMed ID: 15077073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage.
    Creech CB; Johnson BG; Alsentzer AR; Hohenboken M; Edwards KM; Talbot TR
    Vaccine; 2009 Dec; 28(1):256-60. PubMed ID: 19799842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of Staphylococcus aureus infections: advances in vaccine development.
    Shinefield HR; Black S
    Expert Rev Vaccines; 2005 Oct; 4(5):669-76. PubMed ID: 16221068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.
    Verdier I; Durand G; Bes M; Taylor KL; Lina G; Vandenesch F; Fattom AI; Etienne J
    J Clin Microbiol; 2007 Mar; 45(3):725-9. PubMed ID: 17202275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia.
    Roghmann M; Taylor KL; Gupte A; Zhan M; Johnson JA; Cross A; Edelman R; Fattom AI
    J Hosp Infect; 2005 Jan; 59(1):27-32. PubMed ID: 15571850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines.
    Broughan J; Anderson R; Anderson AS
    Expert Rev Vaccines; 2011 May; 10(5):695-708. PubMed ID: 21604989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staphylococcus aureus antigens and challenges in vaccine development.
    Middleton JR
    Expert Rev Vaccines; 2008 Aug; 7(6):805-15. PubMed ID: 18665778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
    Shinefield HR
    Vaccine; 2006 Apr; 24 Suppl 2():S2-65-9. PubMed ID: 16823932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O-Acetylation is essential for functional antibody generation against Staphylococcus aureus capsular polysaccharide.
    Scully IL; Pavliak V; Timofeyeva Y; Liu Y; Singer C; Anderson AS
    Hum Vaccin Immunother; 2018 Jan; 14(1):81-84. PubMed ID: 29182428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide.
    Maira-Litran T; Kropec A; Goldmann D; Pier GB
    Vaccine; 2004 Feb; 22(7):872-9. PubMed ID: 15040940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic strategies to combat staphylococcal infections.
    Ohlsen K; Lorenz U
    Int J Med Microbiol; 2010 Aug; 300(6):402-10. PubMed ID: 20547101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic approaches against Staphylococcus aureus.
    Verkaik NJ; van Wamel WJ; van Belkum A
    Immunotherapy; 2011 Sep; 3(9):1063-73. PubMed ID: 21913829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus.
    von Eiff C; Taylor KL; Mellmann A; Fattom AI; Friedrich AW; Peters G; Becker K
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):297-302. PubMed ID: 17376630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection.
    Rivas JM; Speziale P; Patti JM; Höök M
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):223-7. PubMed ID: 15603256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.